Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of bortezomib when given
together with decitabine in treating patients with acute myeloid leukemia. Bortezomib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving bortezomib
together with decitabine may kill more cancer cells.